1st Quarter - Amendment

PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
—
Expenses
$116,150
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 23, 2012 $56,150 Replaced
1st Quarter - Amendment (this page) Apr 24, 2012 $116,150 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, drug shortages (PDUFA reauthorization), essential health benefits, comparative effectiveness research

Foreign entity interest: Grifols S.A., Cangene Corp.

LobbyistCovered position, as disclosed
JULIE BIRKOFER —
JOHN EVERETT CROSLAND —
KYM HOWARTH KILBOURNE —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.